EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs

Provides roadmap to commercial agreement based on shared objective to secure patient access to innovative and cost-effective cancer medicines
Agreement with one of the largest public healthcare systems globally demonstrates EQRx’s commitment to offering new medicines to patients at radically lower prices
EQRx’s lead cancer programs, aumolertinib and sugemalimab, have received Innovation Passport designations through the Innovative Licensing and Access Pathway (ILAP)
CAMBRIDGE, Mass., October 19, 2021 –( BUSINESS WIRE )–EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced it has signed a memorandum of …

Read the source article at sg.finance.yahoo.com
2021-10-19 19:33:00